The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:

1. Large Language Model GPT-4 Compared to Endocrinologist Responses on Initial Choice of Antidiabetic Medication – Diabetes Care. Discussion by:
Guest:
James Flory, M.D.
Associate Professor
in the Weill Cornell Medical College
Associate Attending at the Memorial Sloan Kettering Cancer Center.

2. Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years – BMJ Medicine. Discussion by:
Guest:
Kimberly Alfonso, MD,
Resident– Family Medicine Residency Program
Jefferson Health – Abington

3. Fluoride Exposure and Children’s IQ Scores A Systematic Review and Meta-Analysis . JAMA Pediatrics 2024. Discussion by:
Guest:
Elyssa Heisey, DO
Resident– Family Medicine Residency Program
Jefferson Health – Abington

Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.

This Podcast Episode does not offer CME/CE Credit.

Send us a text about this episode.

Send us a text about this episode.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/using-newer-agents-in-chronic-hyperkalemia-management-9953

Summary
In this concise CME/CE podcast, a cardiologist and primary care physician review hyperkalemia management options that safely allow continuing GDMT for patients with heart failure or CKD. Using case examples, the clinicians provide education on individualizing treatment and addressing disparities in care.

Learning Objective
At the conclusion of this activity, participants should be better able to:

• Identify practical aspects of using potassium binders for treating hyperkalemia and optimizing GDMT to achieve equitable care for patients with HF and CKD

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Send us a text about this episode.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/managing-the-burden-of-hyperkalemia-9952

Summary
In this concise CME/CE podcast, a cardiologist and a family physician discuss risks associated with hyperkalemia in patients being treated for heart failure or chronic kidney disease (CKD)—including the risks that accompany down-titration or discontinuation of RAASi therapy.

Drs. Javed Butler and Neil Skolnik provide guidance on which patients are most at risk and review the use of potassium binders that can manage hyperkalemia without compromising the crucial use of guideline-directed medical therapy (GDMT). By the end of this podcast episode, listeners will feel much more confident in their ability to safely and effectively address hyperkalemia in patients with heart failure or CKD.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Describe the disparities and clinical implications of hyperkalemia in patients with HF and CKD in terms of optimizing guideline-directed medical therapy (GDMT) and outcomes
• Discuss the safety and effectiveness of potassium binders in reducing potassium and optimizing GDMT in patients with HF and CKD

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Send us a text about this episode.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.